Illumina, Inc.
Illumina Completes Spin-Off of GRAIL and Releases Pro Forma Financials
Summary
On June 24, 2024, Illumina, Inc. completed the spin-off of its subsidiary GRAIL, Inc. Illumina distributed one share of GRAIL common stock for every six shares of Illumina common stock held by stockholders as of June 13, 2024. Following the spin-off, Illumina will no longer consolidate GRAIL within its financial results. The company also provided unaudited pro forma condensed consolidated financial statements to reflect the spin-off.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement